Nektar Therapeutics (NKTR) Reports Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at.
“Botched math” in calculating clinical data for an autoimmune disease drug is one of the allegations Nektar Therapeutics makes in a legal complaint against Eli Lilly. The biotech claims its former partner tried to disadvantage the asset in order to advance development of another drug it acquired in a billion dollar deal.
Nektar Therapeutics (NASDAQ:NKTR – Get Rating) – William Blair reduced their Q2 2023 earnings per share estimates for shares of Nektar Therapeutics in a note issued to investors on Wednesday, May 10th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn ($0.27) per share for the quarter, down from their prior […]